Recent Company News

• 05:05 PM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:03 AM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 12:41 AM ET Jul 16, 2025
  

  UCB initiated buy at Goldman Sachs (€170.70, 0.00)

• 01:10 AM ET Jul 08, 2025
  

  UCB to present 15 abstracts from its targeted neurology portfolio at the European Pediatric Neurology Society (EPNS) Congress, Munich, Germany, July 8-12, 2025 (€169.90, 0.00)

• 03:07 AM ET Jul 02, 2025
  

  UCB upgraded to buy from neutral at BofA (pre-open) (€166.85, 0.00)

• 04:16 AM ET Jun 27, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:52 AM ET Jun 27, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:10 AM ET Jun 27, 2025
  

  UCB's GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder shows positive results (€168.80, 0.00)